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Background: The optimal treatment of elderly patients with Hodgkin’s lymphoma (HL) is still a matter of debate.
Since many of these patients receive combined modality treatment, we evaluated the impact of different radiation field
sizes, that is extended-field (EF) or involved-field (IF) technique when given after four cycles of chemotherapy.
Patients and methods: In the multicenter HD8 study of the German Hodgkin Study Group, 1204 patients with
early-stage unfavorable HL were randomized to receive four cycles of chemotherapy followed by either radiotherapy
(RT) of 30 Gy EF + 10 Gy to bulky disease (arm A) or 30 Gy IF + 10 Gy to bulky disease (arm B). A total of 1064 patients
were assessable for the analysis. Of these, 89 patients (8.4%) were 60 years or older.
Results: Elderly patients had a poorer risk profile. Acute toxicity from RT was more pronounced in elderly patients
receiving EF-RT compared with IF-RT [World Health Organization (WHO) grade 3/4: 26.5% versus 8.6%)]. Freedom
from treatment failure (FFTF, 64% versus 87%) and overall survival (OS, 70% versus 94%) after 5 years was lower in
elderly patients compared with younger patients. Importantly, elderly patients had poorer outcome when treated with
EF-RT compared with IF-RT in terms of FFTF (58% versus 70%; P = 0.034) and OS (59% versus 81%; P = 0.008).
Conclusion: Elderly patients with early-stage unfavorable HL generally have a poorer risk profile and outcome when
compared with younger patients. Treatment with EF-RT instead of IF-RT after chemotherapy has a negative impact on
survival of elderly patients and should be avoided.
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introduction
The prognosis for patients with Hodgkin’s lymphoma (HL) has
substantially improved over the last decades. This success is
mainly attributed to the introduction and optimization of
effective chemotherapy regimens and progress in radiation
techniques. With complete remission (CR) rates exceeding 95%
and 5-year overall survival (OS) of >80%, aim of prospectively
randomized trials has increasingly shifted towards potentially less
toxic treatments. One example is the HD8 study of the German
Hodgkin Study Group (GHSG) demonstrating that involved-
field radiotherapy (IF-RT) is equally effective when compared
with extended-field radiotherapy (EF-RT) after four cycles of
chemotherapy for patients with early-stage unfavorable HL [1].
In contrast to younger patients, in elderly patients with HL
the prognosis is still unsatisfactory. Advanced age at
presentation is one of the strongest negative risk factors.
Different study groups showed significantly poorer outcome for
elderly HL patients compared with younger patients when
similar treatments were given [2–15]. Generally, factors such as
more aggressive disease, shorter history of disease, more
frequent diagnosis of advanced stage [2–4], comorbidity [5],
poor tolerance of treatment [6], failure to maintain dose
intensity [7–10], shorter survival after relapse [11, 12], and
death due to other causes [13] contribute to the poorer outcome
in elderly patients.
Thus, clinical interest increasingly focuses on this high-risk
group of HL patients. A recent comprehensive analysis of GHSG
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trials’ HD5–9 showed that elderly patients present with poorer
risk factors, experience more treatment-associated toxicity,
receive lower dose intensity, and suffer from higher mortality
[14]. Furthermore, intensification of treatment that has been
shown to improve outcome for younger HL patients cannot easily
be applied to elderly patients. The only prospectively randomized
trial in this age group, HD9elderly for patients with advanced-
stage HL, reported better tumor control related to intensified
chemotherapy which was offset by higher mortality [15].
Since RT is another key element in the treatment of HL,
we revisited the HD8 data for possible differences with regard
to the type of RT applied.
patients and methods
patients
From February 1993 to March 1998, newly diagnosed patients with biopsy-
proven HL in clinical stages I and II with selected risk factors as well as
patients in clinical stage IIIA without risk factors were enrolled into the
GHSG HD8 multicenter trial. Risk factors included the following: (a) large
mediastinal mass (‡1/3 of maximal thorax diameter, determined by
posterior–anterior chest radiography); (b) extranodal disease; (c) massive
spleen involvement (diffuse infiltrations or more than five focal lesions); (d)
elevated erythrocyte sedimentation rate (‡50 mm/h in patients without B
symptoms; ‡30 mm/h in patients with B symptoms); or (e) three or more
nodal areas involved. All patients with clinical stage IIB with risk factors
a, b, or c were allocated to the study for advanced stages.
Patients had to be between 16 and 75 years of age, in good general
condition (Karnofsky performance status ‡70%), not previously treated,
and free of concurrent infection. Patients with impaired heart, lung, liver, or
kidney function; previous malignant disease; or HIV-positive status were not
included. Minimal hematological requirements included a WBC count
>3000/ll and platelet count >100,000/ll. Patients were also excluded if they
were pregnant or lactating. Biopsy material was judged by the local
pathologist and then centrally reviewed by at least one member of a panel of
six HL expert pathologists. Composite lymphomas were excluded. Routine
staging procedures included medical history; physical examination; chest
radiography; computed tomography of the chest, abdomen, and pelvis; bone
marrow biopsy; skeletal scintigraphy; serum chemistry; lung function tests;
and echocardiography. Each patient signed an informed consent form which
was based on Institutional Review Board guidelines.
study design
Patients were registered in the HD8 trial and randomly assigned to the two
treatment arms as previously described [1]. In arm A, patients received two
cycles of COPP/ABVD (COPP alternating with ABVD in every cycle)
followed by 30-Gy RT to the EF + 10 Gy to initial bulky disease (single lymph
node involvement or conglomerate mass of ‡5 cm in any diameter). In arm
B, the same chemotherapy was applied followed by 30-Gy RT to the IF + 10
Gy to initial bulky disease.
chemotherapy
Patients were scheduled to receive a total of two cycles of COPP alternating
with two cycles of ABVD. COPP was given from days 1 to 14
[cyclophosphamide 650 mg/m2 i.v. day 1 + 8; vincristine 1.4 mg/m2 (max.
2 mg/m2) i.v. day 1 + 8; procarbacine 100 mg/m2 p.o. day 1–14; prednisone
40 mg/m2 p.o. day 1–14], followed by ABVD on days 29 and 43
(doxorubicin 25 mg/m2 i.v. day 29 + 43; bleomycin 10 mg/m2 i.v. day 29 + 43;
vinblastine 6 mg/m2 i.v. day 29 + 43; dacarbazine 375 mg/m2 i.v. day 29 + 43).
Treatment application, delay, dose reduction, and the use of hematopoietic
growth factors were carried out as previously described [1].
radiotherapy
RT was planned centrally by an expert radiation oncology review panel.
According to treatment arm, patients received 30 Gy in either the EF
technique (arm A) or IF technique (arm B) for a period of 3–3.5 weeks.
Additional RT of 10 Gy was given during the fourth week to areas of initial
bulky disease. For patients presenting with HL on both sides of the
diaphragm, EF-RT was applied in two separate series. Single fraction size was
1.8–2.0 Gy and was given five times a week.
EF-RT included the involved lymph node region as well as all anatomic
and functionally adjacent but clinically uninvolved lymph node regions.
Generally, EF-RT indicated treatment delivered to regions on both sides of
the diaphragm. For a supradiaphragmatic involvement, such as the
mediastinal nodes, the EF-RT volume included a mantle field and also the
para-aortic area (inferior border L4–5 interspace), the splenic hilar region,
and the spleen if necessary. The mantle field extended from the inferior
portion of the mastoid to the level of the insertion of the diaphragm.
Individually contoured lung blocks were designed to conform to the
patient’s anatomy and tumor extension. The first series of radiation adding
up to 16 Gy total were delivered to the initial mediastinal–hilar lymph node
enlargement. Subsequently, the mediastinal–hilar contour was modified and
included only the extension after chemotherapy. A subdiaphragmatic
radiation field was similar to an inverted Y, including the retroperitoneal
and pelvic lymph nodes and the spleen. In addition, a mantle field without
the upper cervical and axillary region was irradiated (T field). If there was an
involvement in the upper cervical region or the Waldeyer’s ring only,
radiation therapy was administered to supradiaphragmatic regions only.
The EF-RT consisted of a mantle field plus additional Waldeyer fields.
If only the inguinal nodes were involved, the EF-RT was applied in the
inverted-Y technique.
IF-RT was administered to all initially involved lymph node regions. All
these regions were treated in one field, if possible, for example a T field for
supraclavicular and mediastinal involvement. The procedure for the design
of the field contour of bulky mediastinal disease was the same as for EF-RT.
statistical analysis
Response criteria (CR, partial remission, no change, and progressive disease)
as well as selection criteria for analysis of acute toxic effects during RT were
used as previously described [1]. The Mann–Whitney U test was applied for
arm comparisons of acute toxicity (WHO grades 1 to 4); for categorical data,
Fisher’s exact test was used. Freedom from treatment failure (FFTF) and OS
rates were analyzed according to the Kaplan–Meier method [16]. The main
end point of the trial was FFTF after the start of RT. FFTF was defined from
the start of RT to the first of the following events: progression during RT,
lack of CR at the end of protocol treatment, relapse, or death from any cause.
The arm comparison for OS was also based on the time calculated from the
start of RT until death from any cause or date of last information,
respectively. Kaplan–Meier estimates were compared using the log-rank
test. A P value <0.05 was considered significant in this explorative
retrospective analysis without adjustment for multiplicity. All statistical
analyses were carried out with SAS 8.2 (SAS Institute Inc., Cary, NC).
results
patient characteristics
A total of 1204 patients were randomly assigned to the two
treatment arms. The median observation time was 55 months
for both treatment groups. The flow of patients through the
various stages of the trial as well as reasons for exclusion and
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discontinuation were presented in detail elsewhere [1]. The 1064
patients actually starting RT (informative patients) provide the
basis for the current analysis. Of these, 89 patients (8.4%) were
60 years or older and 975 patients were younger than 60 years.
Demographic data and the number of patients according to
treatment arm are given in Table 1.
Generally, there were more negative risk factors, such as B
symptoms, elevated erythrocyte sedimentation rate, and poorer
Karnofsky performance status, in the elderly group. On the
other hand, there were fewer large mediastinal masses, a smaller
number of lymph node areas involved, and fewer bulky tumors
in elderly patients. Younger patients more often presented with
nodular sclerosis subtype, whereas the frequency of mixed-
cellularity subtype was higher in elderly patients. Patient
characteristics are shown in Table 2.
administration of treatment and toxicity
All patients were scheduled to the same initial chemotherapy
consisting of two cycles of COPP alternating with two cycles of
ABVD. The most commonly observed toxic effects during
chemotherapy included WHO grade 3 or 4 leucopenia (71.6%
for patients ‡60 years; 56.2% for patients <60 years), alopecia
(36.4% for patients ‡60 years; 23.8% for patients <60 years),
and nausea (6.8% for patients ‡60 years; 11.1% for patients
<60 years) with no difference between study arms. Other
acute grade 3 or 4 toxic effects during chemotherapy occurred in
<2% of all patients.
Acute toxicity during RT was more pronounced in patients
undergoing EF-RT (arm A), including nausea, hematological,
pharyngeal, and gastrointestinal (GI) toxicity [1]. A total of
11.3% of all patients had WHO grade 3 or 4 toxicity during RT.
Compared with the group of patients younger than 60 years,
elderly patients more often suffered from severe toxicity
especially those assigned to the EF-RT arm (26.5% in arm A and
8.6% in arm B, P < 0.05). As shown in Table 3, in elderly
patients especially nausea and leucopenia grade 3 and 4 were
more pronounced in the EF-RT arm with 3 of 34 (8.8%) versus
0 of 35 in the IF-RT arm.
treatment outcome, causes of death, and
secondary malignancies
Response rates, causes of death, and secondary malignancies
according to age and treatment are shown in Table 4. In all,
97.8% of all patients achieved CR or CR unconfirmed, without
notable differences with respect to age and treatment modality.
In contrast to younger patients, however, more elderly patients
died during follow-up. Causes of death included HL, toxicity
from primary or salvage treatment, secondary malignancies, and
cardiovascular or pulmonary disease. The total number of
secondary malignances was 39 (3.7%), with 10 (11.2%)
occurring in elderly patients and 29 (3.0%) in younger patients.
So far, in elderly patients, there were six secondary malignancies
after EF-RT (13.0%) as compared with four after IF-RT (9.3%).
survival
In the current analysis, FFTF and OS was remarkably lower for
elderly compared with younger patients: after a median follow-
up of 60 months, the 5-year FFTF was 64% [95% confidence
interval (CI) 52% to 76%) in patients ‡60 years and 87% (85%
to 90%) in patients <60 years (log-rank, P < 0.001)]. The 5-year
OS was 70% (59% to 81%) and 94% (92% to 96%), respectively
(log-rank, P < 0.001) as shown in Figure 1.
Most importantly, elderly patients showed different outcomes
according to the type of RT received: patients older than 60 had
Table 2. Patient characteristics
% of elderly
patients ‡60 years
% of younger
patients <60 years
Arm A
(n = 46)
Arm B
(n = 43)
Arm A
(n = 486)
Arm B
(n = 489)
Stage
IA 8.7 14.0 5.3 3.7
IB 2.2 7.0 3.5 2.2
IIA 50.0 44.2 68.1 69.5
IIB 37.0 30.2 20.6 22.5
IIIA 2.2 4.7 2.5 2.0
Risk factors
Large mediastinal mass 8.7 7.0 18.1 20.4
Massive spleen involvement 2.2 2.3 0.2 0.2
Extranodal involvement 6.5 11.6 7.2 7.2
High ESR (n = 1061) 76.1 62.8 44.7 49.0
‡3 Lymph node areas 56.5 46.5 66.7 65.8
Bulky disease (n = 1057) 47.7 53.5 62.6 60.7
Laparotomy carried
out (n = 1025)
9.1 7.1 4.3 3.0
Karnofsky performance
status (n = 1040)
80–100 86.7 95.3 99.8 98.7
<80 13.3 4.7 0.2 1.3
Review histology (n = 807)
LP/LR 5.1 0 2.2 2.7
NS 43.6 42.4 74.0 77.0
MC 35.9 45.5 16.4 15.4
LD 0 0 0.8 0.3
Unclassifiable or other 15.4 12.1 6.6 4.6
ESR, erythrocyte sedimentation rate; LP, lymphocyte predominant;
LR, lymphocyte rich; NS, nodular sclerosis; MC, mixed cellularity;
LD, lymphocyte depleted.
Table 1. Demographic characteristics
Elderly patients
‡60 years
Younger patients
<60 years
Arm A, n Arm B, n Arm A, n Arm B, n
Total number of
eligible patients
46 43 486 489
Age, years
16–29 – – 240 243
30–44 – – 173 180
45–59 – – 73 66
60–75 46 43 – –
Median age 65.5 65 30 30
Sex
Male 24 25 232 242
Female 22 18 254 247
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a significantly inferior outcome when treated with EF-RT as
compared with IF-RT, in terms of both, FFTF (EF: 58%, 42%
to 73%; IF: 70%, 52% to 88%; log-rank P = 0.034) and OS
(EF: 59%, 44% to 75%; IF: 81%, 67% to 95%; log-rank P =
0.008) (Figure 2).
discussion
The objective of the current analysis was to compare toxicity
and treatment outcome for elderly and younger HL patients
depending on the technique of RT applied (EF or IF). The
following results emerge from this study: first, acute toxicity
from RT was more pronounced in the group of patients
receiving EF-RT. Second, FFTF (64% versus 87%) and OS (70%
versus 94%) at 5 years was lower in elderly patients when
compared with younger patients receiving identical treatment.
Third, elderly patients who were treated in the EF-RT arm
had a significantly inferior outcome compared with elderly
patients in the IF-RT arm with a difference of 12% for FFTF
and 22% for OS after 5 years.
Elderly HL patients with early-stage disease and adequate
organ function qualify for very similar curative approaches as
younger patients. The treatment generally involves combined
modality treatment including chemotherapy and RT. Even
selected elderly patients, however, have a significantly poorer
outcome when compared with younger HL patients due to
poorer tolerance of treatment resulting in less dose intensity.
Other factors include shorter survival after relapse, more
comorbidity, and others [2–13]. A recent GHSG analysis on
373 elderly HL patients (‡60 years) demonstrated that higher
mortality during treatment as well as lower dose intensity were
the major factors explaining the poorer overall outcome of elderly
HL patients [14]. In an attempt to improve the poor prognosis
for elderly HL patients, the GHSG conducted the HD9elderly
trial in which patients with advanced disease aging 60 years and
more were randomized between eight courses of COPP–ABVD
or BEACOPP (combination therapy with bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine and
prednisone) baseline. The better tumor control achieved with
BEACOPP baseline, however, was offset by more toxicity and
did not translate into better outcome [15].
Older age at presentation was also described as negative risk
factor in patients undergoing treatment of other malignancies:
in a population-based study including 381 patients with
aggressive non-Hodgkin’s lymphoma (NHL), the proportion of
patients who received chemotherapy decreased with older age.
There were more patients requiring dose reduction due to
comorbidity, poor performance status, or chemotherapy-related
Table 4. Treatment outcome and causes of death
% of elderly
patients
‡60 years
% of younger
patients
<60 years
% of all
patients
(n = 1064)
Arm A
(n = 46)
Arm B
(n = 43)
Arm A
(n = 486)
Arm B
(n = 489)
Response
CR/CRu 93.5 100 99.0 96.9 97.8
PR 2.2 0.0 0.4 0.4 0.5
NC 0.0 0.0 0.0 0.2 0.1
PRO 2.2 0.0 0.6 2.0 1.3
Unknown 2.2 0.0 0.0 0.4 0.3
Death 41.3 16.3 4.9 5.5 7.2
Causes of death
HL 4.3 2.3 2.1 2.2 2.3
Secondary
malignancy
8.7 4.7 1.6 1.2 1.9
Toxicity
(primary RT)
2.2 0.0 0.2 0.0 0.2
Toxicity
(salvage therapy)
0.0 0.0 0.4 0.6 0.5
Cardiovascular 4.3 4.7 0.0 0.8 0.8
Lung 6.5 0.0 0.0 0.2 0.4
Other or unknown 15.2 4.7 0.6 0.4 1.3
Secondary
malignancies
13.0 9.3 3.7 2.2 3.7
AML or MDS 8.7 2.3 0.6 0.2 0.8
NHL 0.0 0.0 1.0 0.8 0.8
Solid tumor 4.3 7.0 2.1 1.2 2.0
CR, complete remission; CRu, complete remission unconfirmed;
PR, partial remission; HL, Hodgkin’s lymphoma; NC, no change;
PRO, early progression; RT, radiotherapy; AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma;
SM, secondary malignancy.
Table 3. Radiotherapy-associated acute toxicity (WHO grade 1/2 and 3/4)
WHO grade % of elderly
patients ‡60 years
% of younger
patients <60 years
% of all
patients
(n = 925)in Arm A
(n = 35)
in Arm B
(n = 35)
in Arm A
(n = 441)
in Arm B
(n = 414)
Total
1/2 67.6 80.0 82.3 88.8 84.6
3/4 26.5 8.6 14.4 6.8 11.3
Hematological toxicity
Leucopenia
1/2 47.1 25.7 44.5 31.5 38.1
3/4 8.8 0.0 4.1 2.4 3.4
Thrombopenia
1/2 23.5 2.9 14.7 5.6 10.5
3/4 2.9 2.9 1.1 0.0 0.8
Anemia
1/2 20.6 5.7 8.3 6.6 7.9
3/4 2.9 0.0 0.5 0.0 0.3
Other toxicity (‡1.0%)
Nausea
1/2 32.4 28.6 56.7 27.9 41.8
3/4 8.8 0.0 7.6 1.5 4.6
Skin
1/2 55.9 37.1 46.3 49.4 47.7
3/4 2.9 2.9 1.8 2.0 2.0
Esophagus
1/2 55.9 28.6 43.6 44.3 43.8
3/4 0.0 0.0 1.4 1.0 1.1
Pharynx
1/2 50.0 22.9 47.5 41.1 43.8
3/4 2.9 2.9 1.1 0.5 1.0
WHO, World Health Organization.
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toxicity [17]. Similar factors contributing to a poorer OS in
elderly patients were found in patients with acute myeloid
leukemia (AML) and chronic myeloid leukemia [18, 19]. Thus,
new approaches for elderly patients are warranted. New
regimens specifically targeted at elderly HL patients, such as
vinblastine, cyclophosphamide, procarbazine, etoposide,
mitoxantrone and bleomycin (VEPEMB) [20], vincristine,
doxorubicin, bleomycin, etoposide and prednisone (OBDEP)
[21], bleomycin, doxorubicin, cyclophosphamide, vincristine,
procarbacine and prednisone (BACOPP) [22], and prednisone,
vinblastine, doxorubicin and gemcitabine (PVAG) [23], are
currently being evaluated by different study groups.
To our knowledge, this is the first report derived from
a prospective controlled study identifying significantly more
mortality and toxicity in elderly patients when receiving larger
field RT. Although combined modality treatment including
EF-RT resulted in similar responses as compared with IF-RT,
there was significantly poorer OS associated with more toxicity
in elderly patients. Radiation-induced effects, including nausea,
hematological toxicity, pharyngeal, and GI toxicity, were
clearly more often seen in elderly patients undergoing EF-RT.
More GI toxicity from EF-RT is due to the larger radiation
volume including abdominal regions in patients with
supradiaphragmatic involvement only [24].
The reduction of RT field size seems to be essential in order to
reduce long-term sequelae of treatment. Patients undergoing
mantle field RT have a higher risk of late cardiac and pulmonary
disease [25–27]. Furthermore, patients who receive large
radiation fields, either alone or in combination with
chemotherapy more often encounter secondary malignancies,
such as AML [28], NHL [29], and solid tumors [30–34]. The
relative risk of secondary cancers increases with radiation dose
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Figure 1. Kaplan–Meier analysis of (A) freedom from treatment failure (FFTF) and (B) overall survival (OS) after start of radiotherapy according to
age (<60 years and ‡60 years).
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and field size [30–34]. In the current analysis, 11.2% secondary
malignancies occurred in elderly patients and 3.0% in younger
patients. Though the numbers were small and the follow-up is
still relatively short, there were more secondary malignancies in
the EF-RT arm; 13.0% versus 9.3% in elderly and 3.7% versus
2.2% in younger patients.
As a consequence from the results of the GHSG HD8 trial and
similar data by the European Organisation for Research and
Treatment of Cancer (EORTC), IF-RT has become the new
standard in combined modality treatment which should reduce
acute and long-term toxicity [1, 35]. For elderly patients, current
approaches include RT applied to residual lesions only or no RT
at all [23]. Whether a further reduction of RT dose is possible
while maintaining the excellent results in the whole HL
population is subject to recently conducted and ongoing clinical
trials. In the GHSG HD11 trial, patients with early unfavorable
HL were allocated to four cycles of chemotherapy followed by
either 30- or 20-Gy IF-RT. Interim results at 2 years indicate no
significant difference in treatment outcome [36]. Similar interim
results were observed for early favorable stages in the GHSG
HD10 trial [37]. In addition, the H9F trial of the EORTC and
Groupe d’Etude des Lymphomes de L’Adulte (GELA) evaluated
a possible dose reduction of RT (36 or 20 Gy or no RT) after
six cycles of epirubicin, bleomycin, vinblastine and prednisone
(EBVP) chemotherapy [38]. Here, the arm without RT had to
be closed prematurely due to an unexpected high relapse rate.
Thus, the use of chemotherapy only in early-stage HL is still
experimental. Furthermore, development of new therapeutic
approaches such as immunotherapy with monoclonal
antibodies associated with less toxicity is urgently needed [39].
Taken together, our data demonstrate that outcome of
patients aged 60 years or older clearly depends on the modality
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Figure 2. Kaplan–Meier analysis of (A) freedom from treatment failure (FFTF) and (B) overall survival (OS) after start of radiotherapy (RT) of elderly
patients (‡60 years) according to treatment arm; arm A: chemotherapy and extended-field RT and arm B: chemotherapy and involved-field RT.
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of RT applied after chemotherapy for early-stage unfavorable
HL. In this group of high-risk HL patients, application of EF-
RT instead of IF-RT resulted in significantly lower FFTF and
survival and should be avoided in future studies in the elderly.
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